Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Research Article

Expression, Purification and Characterization of a GII.4 Norovirus Protease from Minerva Virus

Author(s): Benjamin D. Kuiper, Kendall M. Muzzarelli, Bradley J. Keusch, Joshua Holcomb, Franck Amblard, Peng Liu, Shaoman Zhou, Iulia A. Kovari, Zhe Yang, Raymond F. Schinazi and Ladislau C. Kovari*

Volume 18, Issue 3, 2018

Page: [224 - 232] Pages: 9

DOI: 10.2174/1871526518666180521091158

Price: $65

Abstract

Background: Noroviruses are the leading cause of acute gastroenteritis worldwide. Norovirus proteases, which are responsible for cleavage of the viral polyprotein, have become an attractive drug target to treat norovirus infections. Genogroup II (GII) noroviruses are responsible for a majority of outbreaks; however, limited data exists regarding GII norovirus proteases.

Methods: We report here successful expression, purification, characterization, and inhibition of the Minerva virus protease (MVpro), a genogroup II genotype 4 (GII.4) norovirus protease. We observed MVpro as both a monomer and dimer in solution through sizeexclusion chromatography. In addition, MVpro cleaves the synthetic substrate mimicking the MVpro NS2/NS3 cleavage site more efficiently than other norovirus proteases such as the Norwalk virus protease (GI.1) and the MD145 protease (GII.4).

Results and Conclusion: Compound A, a potent inhibitor of MVpro, is a good starting point for the design of inhibitors to target GII.4 noroviruses. Furthermore, the results presented here will allow for future characterization of MVpro inhibitors as they are synthesized.

Keywords: Noroviruses, Polyprotein, Chromatography, Potent inhibitor, MVpro inhibitors, Purification.

Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy